Mineralys Therapeutics, Inc. MLYS

MLYS Company Overview

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, cardiovascular disease, chronic kidney disease, and related metabolic disorders driven by dysregulated aldosterone biology. The company operates within the biotechnology and specialty pharmaceutical industries, with its primary emphasis on therapies targeting the mineralocorticoid pathway. Mineralys’ lead product candidate is lorundrostat, an investigational aldosterone synthase inhibitor being evaluated for treatment-resistant hypertension and uncontrolled hypertension. The company’s business model is centered on clinical development, regulatory advancement, and eventual commercialization of novel cardiovascular therapies.

Mineralys was founded in 2019 and is headquartered in Pennsylvania, United States. The company emerged with a strategy focused on selectively inhibiting aldosterone production while aiming to avoid cortisol-related side effects associated with earlier compounds in the therapeutic category. Since its formation, Mineralys has advanced lorundrostat through multiple mid- and late-stage clinical studies, positioning itself within a growing area of cardiovascular therapeutics where unmet medical need remains significant. Public disclosures in SEC filings and investor materials indicate that resistant hypertension and cardiorenal disease are the company’s primary target markets.